CME Travel Academy

Walt Disney World CME Conference Recap: July 17–18, 2026 (2027 Waitlist Open)

What if your next CME requirement came with a side of roller coasters, a waterfront dinner, and a family vacation? That’s exactly what physicians experienced at CME Travel Academy’s Walt Disney World CME Conference, held July 17–18, 2026 at the Drury Plaza Hotel in the Disney Springs® Area, Orlando, Florida. The event has concluded — […]

Walt Disney World CME Conference Recap: July 17–18, 2026 (2027 Waitlist Open) Read More »

Clinical update: 2025 AHA/ACC Hypertension Guidelines for Primary Care

2025 AHA/ACC Hypertension Guidelines: What Every Primary Care Clinician Must Know

For the first time in eight years, the American Heart Association (AHA) and the American College of Cardiology (ACC) have released a comprehensive overhaul of their hypertension guidelines. The 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults arrives at a critical moment: hypertension remains the single most

2025 AHA/ACC Hypertension Guidelines: What Every Primary Care Clinician Must Know Read More »

GINA 2026 Asthma Update featured image with key stats: ICS-formoterol AIR, four new primary-care exacerbation flowcharts, depemokimab Q26-week dosing.

GINA 2026: What’s New in Asthma Management for Primary Care

The Global Initiative for Asthma (GINA) released its 2026 Strategy Report on May 5, 2026, and primary care is squarely in its crosshairs. Asthma affects roughly 25 million Americans, and the majority of routine management still happens in family medicine, internal medicine, and advanced-practice offices rather than in pulmonology subspecialty suites. The 2026 update reflects

GINA 2026: What’s New in Asthma Management for Primary Care Read More »

GLP-1 Receptor Agonists in Obese HFpEF: What the STEP-HFpEF and SUMMIT Trials Mean for Your Practice

Heart failure with preserved ejection fraction (HFpEF) now accounts for more than half of all heart failure diagnoses in the United States, and the proportion continues to rise alongside the obesity epidemic. For decades, clinicians managing this phenotype had few effective pharmacologic tools — spironolactone and SGLT-2 inhibitors offered modest benefit in selected patients, but

GLP-1 Receptor Agonists in Obese HFpEF: What the STEP-HFpEF and SUMMIT Trials Mean for Your Practice Read More »